185 related articles for article (PubMed ID: 37779426)
1. A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
Devasia AJ; Lancman G; Stewart AK
Cancer Res; 2023 Oct; 83(19):3174-3175. PubMed ID: 37779426
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
4. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
6. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
11. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
13. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib combination therapy in multiple myeloma.
Kapoor P; Ramakrishnan V; Rajkumar SV
Semin Hematol; 2012 Jul; 49(3):228-42. PubMed ID: 22726546
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
19. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]